3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Brain Neoplasms
6
Glioblastoma
5
Esophageal Neoplasms
3
Childhood Brain Neoplasm
2
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic carcinoma, familial
1
Pancreatic Intraductal Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Neurodegenerative Diseases
1
Neoplasms
1
Lung Carcinoma Metastatic in the Brain
1
Liver Neoplasms
1
Liver Cirrhosis
1
Ischemic Stroke
1
Hypoxia
1
Hemorrhagic Stroke
1
Head and Neck Neoplasms
1
Glioma
1
Cranial Nerve Diseases
1
Colorectal Neoplasms
1
Chondrosarcoma
1
Interventions
Methotrexate
21
Ifosfamide
21
Cyclophosphamide
19
Doxorubicin
17
Cisplatin
14
Filgrastim
13
Gemcitabine
12
Etoposide
11
Leucovorin
9
apatinib
8
fludarabine
7
glucarpidase
6
Vincristine
6
Temozolomide
6
Radiotherapy
6
Nivolumab
6
Neoadjuvant Therapy
6
Drug Therapy
6
Carboplatin
6
regorafenib
5
cabozantinib
5
Zoledronic Acid
5
Topotecan
5
Mesna
5
Irinotecan
5
Granulocyte Colony-Stimulating Factor
5
Docetaxel
5
pembrolizumab
4
pegfilgrastim
4
camrelizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Osteosarcoma
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts